AA
SNDX icon

ALPS Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

ALPS Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-66,403
Closed -$1.28M – 1036
2024
Q3 		$1.28M Buy
66,403
+110
+0.2% +$2.27K 0.01% 439
2024
Q2 		$1.36M Buy
66,293
+6,369
+11% +$133K 0.01% 397
2024
Q1 		$1.43M Buy
59,924
+11,798
+25% +$263K 0.01% 410
2023
Q4 		$1.04M Sell
48,126
-3,110
-6% -$47.8K 0.01% 468
2023
Q3 		$744K Buy
51,236
+651
+1% +$12.3K 0.01% 540
2023
Q2 		$1.06M Buy
50,585
+5,496
+12% +$114K 0.01% 480
2023
Q1 		$952K Sell
45,089
-317
-0.7% -$7.88K 0.01% 482
2022
Q4 		$1.16M Buy
45,406
+14,554
+47% +$339K 0.01% 420
2022
Q3 		$741K Sell
30,852
-2,504
-8% -$56.2K 0.01% 529
2022
Q2 		$642K Sell
33,356
-23,180
-41% -$386K 0.01% 540
2022
Q1 		$983K Sell
56,536
-1,643
-3% -$27.7K 0.01% 315
2021
Q4 		$1.27M Sell
58,179
-1,414
-2% -$26.1K 0.01% 329
2021
Q3 		$1.14M Sell
59,593
-3,948
-6% -$65.8K 0.01% 378
2021
Q2 		$1.09M Buy
+63,541
New +$1.16M 0.01% 395
2018
Q4 		– Sell
-41,328
Closed -$334K – 931
2018
Q3 		$334K Buy
41,328
+5,477
+15% +$39K ﹤0.01% 888
2018
Q2 		$252K Buy
35,851
+3,139
+10% +$30.8K ﹤0.01% 893
2018
Q1 		$465K Buy
32,712
+5,686
+21% +$60.4K ﹤0.01% 633
2017
Q4 		$237K Buy
27,026
+5,143
+24% +$50.9K ﹤0.01% 782
2017
Q3 		$256K Buy
21,883
+2,030
+10% +$24.9K ﹤0.01% 741
2017
Q2 		$277K Buy
+19,853
New +$227K ﹤0.01% 731
2016
Q4 		– Sell
-22,669
Closed -$344K – 730
2016
Q3 		$344K Sell
22,669
-2,310
-9% -$30.4K ﹤0.01% 633
2016
Q2 		$246K Buy
+24,979
New +$343K ﹤0.01% 591

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ALPS Advisors's SNDX Position: Q4 2024 in Review

ALPS Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q4 2024, closing a stake of 66,403 shares — an estimated $1.28M sold.

ALPS Advisors first reported a position in SNDX in Q2 2016 and held it in 22 quarters. The position peaked at $1.43M in Q1 2024. 215 funds tracked by Wall St. Rank hold SNDX as of Q4 2024.

  • ALPS Advisors reported no remaining Syndax Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • ALPS Advisors sold 66,403 Syndax Pharmaceuticals shares in Q4 2024, an estimated $1.28M.
  • ALPS Advisors first reported a position in Syndax Pharmaceuticals in Q2 2016 and held it in 22 quarters.
  • ALPS Advisors's Syndax Pharmaceuticals position peaked at $1.43M in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2024.

Based on ALPS Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.